Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
Agenus announced that three abstracts evaluating its botensilimab and balstilimab combination have been accepted for poster presentation at the ESMO 2026 Congress in Madrid. The presentations will feature data from investigator-sponsored trials covering neoadjuvant colorectal cancer, refractory metastatic colorectal cancer, and advanced sarcoma.
Key figures
- Balstilimab patients evaluated
- 900
- Bot bal patients treated phase 1 2
- 1300
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.